Strategic Partnerships Immunovant's partnership with FDA for IMVT-1402 trial presents a potential collaboration opportunity for companies offering supportive services or technologies for clinical trials.
Competitor Challenges Immunovant's competitor's failures in pemphigus vulgaris highlight market gaps, offering a chance for Immunovant to leverage its strengths and capture market share.
Investment Influx Recent investments by Rubric Capital Management, WCM Investment Management, and others indicate investor confidence in Immunovant's potential, signaling sales opportunities in supplying services or products to fuel growth.
Acquisition Significance Acquisition of Immunovant by Federated Hermes signifies a potential for strategic partnerships and cross-selling opportunities for companies aligning with Federated Hermes's portfolio.
Market Expansion Immunovant's initiation of a pivotal trial for GD treatment indicates market expansion and offers opportunities for service providers in areas such as logistics, data management, and patient care.
54
$10M$50M
322$50M$100M
51$10M$50M
29
48$10M
11Immunovant uses 8 technology products and services including Amazon CloudFront, Microsoft Word, Google Font API, and more. Explore Immunovant's tech stack below.
| Immunovant Email Formats | Percentage |
| First.Last@immunovant.com | 89% |
| Last.First@immunovant.com | 9% |
| First.Middle@immunovant.com | 1% |
| Last@immunovant.com | 1% |
Biotechnology ResearchNew York, United States201-500 Employees
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. For U.S. residents only.
Company Overview
Media & News
Funding & FinancialsImmunovant has raised a total of $450M of funding over 4 rounds. Their latest funding round was raised on Sep 27, 2023 in the amount of $450M.
Immunovant's revenue is in the range of $50M$100M
Funding & FinancialsImmunovant has raised a total of $450M of funding over 4 rounds. Their latest funding round was raised on Sep 27, 2023 in the amount of $450M.
Immunovant's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com